ClinicalTrials.gg
CompletedNCT00249730Updated Feb 1, 2021

Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.

A Phase 4 interventional study of Sildenafil in Impotence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 39 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
3rd of 50
510 · median 108
Started
2005
with 11 others
Phase 4
30 of 50
none open now
Registered
12th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 3rd largest by enrollment, is one of 12 that started in 2005, is one of 30 in phase 4, and was the 12th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To evaluate the efficacy of Viagra dose titration to 100mg versus 50mg in men with erectile dysfunction, based on responses to the IIEF questionnaire as measured at the beginning and at the end of double blind treatment, comparing the group titrated to 100mg vs. the group maintained on 50mg.

03

Conditions studied

  • Impotence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis of ED by using IIEF-EF domain with score of ≤ 25.
  • Subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse.

Exclusion criteria

Exclusion Criteria:

  • Subjects in whom sexual activity is inadvisable in the opinion of the investigator such as significant cardiovascular disease in the last 6 months; including cardiac failure, myocardial infarction, unstable angina, stroke or (TIA), symptomatic or cardiac arrhythmias including atrial fibrillation.
  • Subjects who are currently taking or are likely to be treated with nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or as aerosols) on either regular or intermittent basis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
510 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in IIEF erectile function domain score at the end of double blind treatment.

Secondary outcomes

  1. Change in other IIEF domain scores; Response to other questionnaires regarding treatment satisfaction, safety and tolerability.

07

Study locations

39 sites
  • Pfizer Investigational Site
    Kitchener, Ontario, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario, Canada
  • Pfizer Investigational Site
    Toronto, Ontario, Canada
  • Pfizer Investigational Site
    St. Leonard, Quebec, Canada
  • Pfizer Investigational Site
    Trois-Rivieres, Quebec, Canada
  • Pfizer Investigational Site
    Lille, France
  • Pfizer Investigational Site
    LYON Cedex 03, France
  • Pfizer Investigational Site
    Montpellier, France
  • Pfizer Investigational Site
    PARIS cedex 18, France
  • Pfizer Investigational Site
    Goudi, Athens, Greece
  • Pfizer Investigational Site
    Patras, Greece
  • Pfizer Investigational Site
    Thessaloniki, Greece
  • Pfizer Investigational Site
    Beer Sheba, Israel
  • Pfizer Investigational Site
    Haifa, Israel
  • Pfizer Investigational Site
    Petach Tikva, Israel
  • Pfizer Investigational Site
    Tel- Aviv, Israel
  • Pfizer Investigational Site
    Bologna, Italy
  • Pfizer Investigational Site
    Firenze, Italy
  • Pfizer Investigational Site
    L'Aquila, Italy
  • Pfizer Investigational Site
    Milano, Italy
  • Pfizer Investigational Site
    Roma, Italy
  • Pfizer Investigational Site
    Moscow, Russian Federation
  • Pfizer Investigational Site
    La Laguna, Santa Cruz De Tenerife, Spain
  • Pfizer Investigational Site
    Alicante, Spain
  • Pfizer Investigational Site
    Barcelona, Spain
  • Pfizer Investigational Site
    Madrid, Spain
  • Pfizer Investigational Site
    Malaga, Spain
  • Pfizer Investigational Site
    Sevilla, Spain
  • Pfizer Investigational Site
    Valencia, Spain
  • Pfizer Investigational Site
    Belmont, Durham, United Kingdom
  • Pfizer Investigational Site
    Ashford, Middlesex, United Kingdom
  • Pfizer Investigational Site
    Weybridge, Surrey, United Kingdom
  • Pfizer Investigational Site
    Chippenham, Wilts., United Kingdom
  • Pfizer Investigational Site
    Trowbridge, Wiltshire, United Kingdom
  • Pfizer Investigational Site
    Bath, United Kingdom
  • Pfizer Investigational Site
    Coventry, United Kingdom
  • Pfizer Investigational Site
    Doncaster, United Kingdom
  • Pfizer Investigational Site
    Dundee, United Kingdom
  • Pfizer Investigational Site
    Glasgow, United Kingdom
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00249730
Responsible party
Sponsor
First posted
Nov 7, 2005
Start date
Oct 2005
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion